The patent owner of the EpiPen is the target of our wrath over its price. However, as I noted in a previous post, there is
The latest scapegoat of the left-EpiPen
The price of the EpiPen is not the real issue. Frankly I don’t know what the fair price is for an EpiPen or how the
Connecticut Treasurer Calls for Re-Evaluation of Pension Returns – Bloomberg
More on states that can’t manage the promises of public employee pensions and put taxpayers at risk. Pure political incompetence! And dare we ask their
The way we think … over the edge … live for today🤑
I recently heard an executive of one of the nations largest home builders say, “With interest rates so low, consumers are looking to buy much
QUINNSCOMMENTARY 